L Perrin

Summary

Affiliation: University Hospital
Country: Switzerland

Publications

  1. pmc Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach
    Dimitrios Paraskevis
    Katholieke Universiteit Leuven, Rega Institute for Medical Research, Minderbroederstraat 10, B 3000 Leuven, Belgium
    Retrovirology 6:49. 2009
  2. pmc New complete genome sequences of human rhinoviruses shed light on their phylogeny and genomic features
    Caroline Tapparel
    Central Laboratory of Virology, Division of Infectious Diseases, University of Geneva Hospitals, Geneva, Switzerland
    BMC Genomics 8:224. 2007
  3. ncbi request reprint Therapeutic vaccination in primary HIV infection, the Quest trial
    Luc Perrin
    Division of Infectious Diseases, University Hospital of Geneva, Geneva, Switzerland
    Vaccine 20:2004-6. 2002
  4. ncbi request reprint Travel and the spread of HIV-1 genetic variants
    Luc Perrin
    Laboratory of Virology, Division of Infectious Diseases, University of Geneva, Switzerland
    Lancet Infect Dis 3:22-7. 2003
  5. ncbi request reprint Virus burden in lymph nodes and blood of subjects with primary human immunodeficiency virus type 1 infection on bitherapy
    L Perrin
    AIDS Centre, Department of Otho Rhino Laryngology, Geneva University Hospital, Switzerland
    J Infect Dis 177:1497-501. 1998
  6. ncbi request reprint Primary HIV infection
    L Perrin
    Laboratory of Virology, Division of Infectious Diseases, Geneva University Hospital, Geneva, Switzerland
    Antivir Ther 4:13-8. 1999
  7. ncbi request reprint Detection of intrahepatic hepatitis C virus replication by strand-specific semi-quantitative RT-PCR: preliminary application to the liver transplantation model
    F Negro
    Division of Gastroenterology and Hepatology, University Hospital, Geneva, Switzerland
    J Hepatol 29:1-11. 1998
  8. ncbi request reprint Zidovudine plus didanosine in primary HIV-1 infection
    L Perrin
    Laboratory of Virology, Geneva University Hospital, Switzerland
    Antivir Ther 2:5-11. 1997
  9. ncbi request reprint Predictive value of codon 215 reverse transcriptase mutation on the efficacy of didanosine in HIV-infected, zidovudine-experienced patients
    S Yerly
    Central Laboratory of Virology, Geneva University Hospital, Switzerland
    Antivir Ther 1:167-71. 1996
  10. ncbi request reprint Nosocomial outbreak of multiple bloodborne viral infections
    S Yerly
    Laboratory of Virology, Division of Infectious Diseases, Geneva University Hospital, Geneva, Switzerland
    J Infect Dis 184:369-72. 2001

Detail Information

Publications72

  1. pmc Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach
    Dimitrios Paraskevis
    Katholieke Universiteit Leuven, Rega Institute for Medical Research, Minderbroederstraat 10, B 3000 Leuven, Belgium
    Retrovirology 6:49. 2009
    ..However the spatial diffusion of the epidemic from the perspective of the virus has not previously been traced...
  2. pmc New complete genome sequences of human rhinoviruses shed light on their phylogeny and genomic features
    Caroline Tapparel
    Central Laboratory of Virology, Division of Infectious Diseases, University of Geneva Hospitals, Geneva, Switzerland
    BMC Genomics 8:224. 2007
    ..The lack of HRV full-length genome sequences and the absence of analysis comparing picornaviruses at the whole genome level limit our knowledge of the genomic features supporting these differences...
  3. ncbi request reprint Therapeutic vaccination in primary HIV infection, the Quest trial
    Luc Perrin
    Division of Infectious Diseases, University Hospital of Geneva, Geneva, Switzerland
    Vaccine 20:2004-6. 2002
  4. ncbi request reprint Travel and the spread of HIV-1 genetic variants
    Luc Perrin
    Laboratory of Virology, Division of Infectious Diseases, University of Geneva, Switzerland
    Lancet Infect Dis 3:22-7. 2003
    ..The spreading of HIV-1 variants has implications for diagnostic, treatment, and vaccine development...
  5. ncbi request reprint Virus burden in lymph nodes and blood of subjects with primary human immunodeficiency virus type 1 infection on bitherapy
    L Perrin
    AIDS Centre, Department of Otho Rhino Laryngology, Geneva University Hospital, Switzerland
    J Infect Dis 177:1497-501. 1998
    ..Six subjects had both detectable plasma viremia and evidence of HIV-1 RNA in lymphoid tissue. The results indicate that absence of detectable HIV RNA in lymphoid tissue is associated with viremia levels of HIV-1 RNA <20 copies/mL...
  6. ncbi request reprint Primary HIV infection
    L Perrin
    Laboratory of Virology, Division of Infectious Diseases, Geneva University Hospital, Geneva, Switzerland
    Antivir Ther 4:13-8. 1999
    ..In clinical practice, adherence is closely linked to the patient's commitment, which is the key parameter for treatment decision...
  7. ncbi request reprint Detection of intrahepatic hepatitis C virus replication by strand-specific semi-quantitative RT-PCR: preliminary application to the liver transplantation model
    F Negro
    Division of Gastroenterology and Hepatology, University Hospital, Geneva, Switzerland
    J Hepatol 29:1-11. 1998
    ....
  8. ncbi request reprint Zidovudine plus didanosine in primary HIV-1 infection
    L Perrin
    Laboratory of Virology, Geneva University Hospital, Switzerland
    Antivir Ther 2:5-11. 1997
    ..These data suggest a higher efficacy of combined therapy compared with zidovudine monotherapy in PHI patients and indicate that control of viraemia for at least 1 year is achievable in PHI patients...
  9. ncbi request reprint Predictive value of codon 215 reverse transcriptase mutation on the efficacy of didanosine in HIV-infected, zidovudine-experienced patients
    S Yerly
    Central Laboratory of Virology, Geneva University Hospital, Switzerland
    Antivir Ther 1:167-71. 1996
    ..03). These data suggest that there was a better initial CD4 response to didanosine therapy in patients with HIV without the mutation at codon 215, but that this response did not translate into increased survival...
  10. ncbi request reprint Nosocomial outbreak of multiple bloodborne viral infections
    S Yerly
    Laboratory of Virology, Division of Infectious Diseases, Geneva University Hospital, Geneva, Switzerland
    J Infect Dis 184:369-72. 2001
    ..HIV and HCV genotypic analyses identified a HIV monophyletic group, whereas 4 clusters of HCV sequences were identified. To our knowledge, this is the largest documented outbreak of nosocomial HIV transmission...
  11. ncbi request reprint IgM anti-hepatitis C virus core antibodies as marker of recurrent hepatitis C after liver transplantation
    F Negro
    Division of Gastroenterology and Hepatology, University Hospital, Geneva, Switzerland
    J Med Virol 56:224-9. 1998
    ..In conclusion, secretion of IgM anti-HCV core antibodies after OLT seems associated with recurrence of HCV-associated liver disease and may have diagnostic significance...
  12. ncbi request reprint Drug resistance mutations in HIV-1-infected subjects during protease inhibitor-containing highly active antiretroviral therapy with nelfinavir or indinavir
    S Yerly
    Laboratory of Virology, University Hospital, Geneva, Switzerland
    Antivir Ther 6:185-9. 2001
    ..In nelfinavir subjects, 30N was the only primary mutation whereas isolated or combined 82A/T and 461/L mutations were detected in indinavir subjects...
  13. ncbi request reprint Acute HIV infection: impact on the spread of HIV and transmission of drug resistance
    S Yerly
    University Hospital of Geneva, 1211 Geneva 14, Switzerland
    AIDS 15:2287-92. 2001
    ....
  14. pmc Resistance to nucleoside analog reverse transcriptase inhibitors mediated by human immunodeficiency virus type 1 p6 protein
    S Peters
    Division of Infectious Diseases, University Hospital, Lausanne, Switzerland
    J Virol 75:9644-53. 2001
    ....
  15. ncbi request reprint Treatment of chronic hepatitis C with alpha-interferon plus ofloxacin in patients not responding to alpha-interferon alone
    F Negro
    Division of Gastroenterology and Hepatology, University Hospital, Geneva, Switzerland
    J Hepatol 29:369-74. 1998
    ..Ofloxacin, a quinolone antibiotic, was recently shown to increase the primary response rate to alpha-interferon treatment of chronic hepatitis C...
  16. ncbi request reprint [Neuromyelitis optica/Devic's syndrome: new perspectives]
    P H Lalive
    Service de Neurologie, Laboratoire de Neuroimmunologie, HUG, 1211 Geneve 14
    Rev Med Suisse 3:950-5. 2007
    ..According to this recent advance, early diagnostic and specific treatment targeting the humoral response should be considered...
  17. ncbi request reprint [Early diagnosis of primary HIV infections: using a combined screening test (p24 antigen and anti-HIV antibodies)]
    S Yerly
    Laboratoire de Virologie, Hôptal Universitaire de Genève
    Schweiz Med Wochenschr 129:319-22. 1999
    ..The new screening assay was positive before a third-generation anti-HIV screening assay gave positive results in 14/34 patients (41%). Using the DUO assay, the mean reduction of the window period was 4 days...
  18. doi request reprint Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children
    Christoph Rudin
    Division of Infectious Diseases, University Children s Hospital, Basel, Switzerland
    Pediatr Infect Dis J 27:431-7. 2008
    ..To evaluate the long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced, initially protease inhibitor (PI)-naive, human immunodeficiency virus (HIV)-1-infected children...
  19. doi request reprint Human herpesvirus-6 variant A encephalomyelitis
    C Pot
    Department of Neurosciences, Division of Neurology, Geneva University Hospital, Micheli du Crest 24, 1211 Geneva 14, Switzerland
    Neurology 70:974-6. 2008
  20. ncbi request reprint Early induction of leukemia inhibitor factor (LIF) in acute HIV-1 infection
    Annelie Tjernlund
    Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    AIDS 20:11-9. 2006
    ..Leukemia inhibitor factor (LIF) is thought to play a substantial role in protecting CD4 T cells in lymphoid tissues (LT) from infection by HIV-1...
  21. ncbi request reprint HIV-1 p24 may persist during long-term highly active antiretroviral therapy, increases little during short treatment breaks, and its rebound after treatment stop correlates with CD4(+) T cell loss
    Jorg Schupbach
    Swiss National Center for Retroviruses, University of Zurich, Zurich, Switzerland
    J Acquir Immune Defic Syndr 40:250-6. 2005
    ..Persisting p24 despite successful HAART may reflect virus replication in reservoirs not represented by plasma viral load and has implications for the concept of therapeutic vaccination...
  22. ncbi request reprint Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management
    Annemarie M J Wensing
    Eijkman Winkler Institute, Department of Virology, University Medical Center Utrecht, The Netherlands
    J Infect Dis 192:958-66. 2005
    ..Widespread transmission of drug-resistant variants has the disturbing potential of limiting future therapy options and affecting the efficacy of postexposure prophylaxis...
  23. ncbi request reprint Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection
    Sabine Kinloch-de Loes
    Department of Medicine, Royal Free Centre for HIV Medicine, Royal Free and University College Medical School, London, United Kingdom
    J Infect Dis 192:607-17. 2005
    ..Our trial design appears to be feasible and safe for testing future immune-boosting strategies...
  24. ncbi request reprint Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey
    Sabine Yerly
    Laboratory of Virology, University of Geneva Hospitals, Geneva, Switzerland
    AIDS 21:2223-9. 2007
    ..Representative prevalence data of transmitted drug-resistant HIV-1 are essential to establish accurate guidelines addressing resistance testing and first-line treatments...
  25. ncbi request reprint Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy
    Gilbert R Kaufmann
    Division of Infectious Diseases and Hospital Epidemiology, Department of Internal Medicine, University Hospital Basel, Basel, Switzerland
    Clin Infect Dis 41:361-72. 2005
    ..We studied the determinants and the clinical relevance of incomplete CD4 T cell restoration...
  26. ncbi request reprint HIV-1 intermittent viraemia in patients treated by non-nucleoside reverse transcriptase inhibitor-based regimen
    Valerie Martinez
    Service de Dermatologie, Hopital Tarnier Cochin, 89, rue d Assas, 75006 Paris, France
    AIDS 19:1065-9. 2005
    ..Risk factors associated with intermittent viraemia and its impact in patients treated by non-nucleoside-reverse-transcriptase-inhibitor-based (NNRTI) regimen need to be evaluated...
  27. ncbi request reprint Clinical performance of the LCx HCV RNA quantitative assay
    Rasa Bertuzis
    Abbott Laboratories, D99G AP20, 100 Abbott Park Road, Abbott Park, IL 60064 6015, USA
    J Virol Methods 123:171-8. 2005
    ..0 specimen results were within 1 log, as were 85.6% (237/277) of paired Roche Monitor 2.0 and Bayer specimen results. These data demonstrate that the LCx assay may be used for quantitation of HCV RNA in HCV-infected individuals...
  28. ncbi request reprint Long-term efficacy after switch from protease inhibitor-containing highly active antiretroviral therapy to abacavir, lamivudine, and zidovudine
    Milos Opravil
    AIDS 18:2213-5. 2004
  29. ncbi request reprint Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor-experienced patients
    Samir Vora
    Laboratory of Virology, Geneva University Hospital, Switzerland
    AIDS 20:35-40. 2006
    ..To develop a clinically relevant genotypic resistance score for boosted atazanavir (ATV) in protease inhibitor-experienced patients...
  30. ncbi request reprint The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes
    David A van de Vijver
    Eijkman Winkler Institute, Department of Virology, University Medical Center Utrecht, G04 614, 3584 CX Utrecht, The Netherlands
    J Acquir Immune Defic Syndr 41:352-60. 2006
    ..This study compared the genetic barrier between subtypes using some 2000 HIV-1 sequences (>600 of non-B subtype) isolated from anti-retroviral-naive patients in Europe...
  31. ncbi request reprint Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types
    Viktor von Wyl
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Ramistr 100, CH 8091 Zurich, Switzerland
    Arch Intern Med 167:1782-90. 2007
    ..Differences between these regimen types in the extent of the emergence of drug resistance on virological failure and the implications for further treatment options have rarely been assessed...
  32. doi request reprint HIV-1 coreceptor usage and CXCR4-specific viral load predict clinical disease progression during combination antiretroviral therapy
    Barbara Weiser
    Division of Infectious Diseases, Wadsworth Center, New York State Department of Health, Albany, New York 12208, USA
    AIDS 22:469-79. 2008
    ..Although combination antiretroviral therapy (cART) dramatically reduces rates of AIDS and death, a minority of patients experience clinical disease progression during treatment...
  33. ncbi request reprint Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005
    Bruno Hoen
    Department of Infectious Diseases, University Medical Centre, Besancon, France
    Clin Infect Dis 45:381-90. 2007
    ..Initiation of antiretroviral therapy during primary human immunodeficiency virus (HIV)-1 infection may confer long-term benefit...
  34. ncbi request reprint Molecular epidemiology: HIV-1 and HCV sequences from Libyan outbreak
    Tulio de Oliveira
    Department of Zoology, University of Oxford, Oxford OX1 3PS, UK
    Nature 444:836-7. 2006
    ....
  35. ncbi request reprint HIV viral load monitoring in resource-limited regions: optional or necessary?
    Alexandra Calmy
    Medecins Sans Frontieres, Access to Medicines Campaign, Geneva, 1211, Switzerland
    Clin Infect Dis 44:128-34. 2007
    ..Rather than considering viral load data to be an unaffordable luxury, efforts should be made to ensure that viral load testing becomes affordable, simple, and easy to use in resource-limited settings...
  36. ncbi request reprint Chronic rhinoviral infection in lung transplant recipients
    Laurent Kaiser
    Central Laboratory of Virology, Division of Infectious Diseases, Department of Internal Medicine, University Hospitals of Geneva, Switzerland
    Am J Respir Crit Care Med 174:1392-9. 2006
    ..Lung transplant recipients are particularly at risk of complications from rhinovirus, the most frequent respiratory virus circulating in the community...
  37. ncbi request reprint CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial
    Jintanat Ananworanich
    HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand
    Lancet 368:459-65. 2006
    ..Stopping antiretroviral therapy in patients with HIV-1 infection can reduce costs and side-effects, but carries the risk of increased immune suppression and emergence of resistance...
  38. ncbi request reprint Efficacy of nelfinavir-based treatment in the central nervous system of HIV-1 infected patients
    Olle Karlström
    Divisions of Infectious Diseases, Karolinska Institute, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Scand J Infect Dis 38:371-4. 2006
    ..Using a highly sensitive method, NFV was detected and quantified in the CSF, although at low values, which could have contributed to the high anti-HIV-1 efficacy of the therapy seen in our subjects...
  39. ncbi request reprint Stable virulence levels in the HIV epidemic of Switzerland over two decades
    Viktor Müller
    Bioinformatics Group, Department of Plant Taxonomy and Ecology, Eotvos Lorand University, Budapest, Hungary
    AIDS 20:889-94. 2006
    ..To determine whether the virulence of HIV-1 has been changing since its introduction into Switzerland...
  40. ncbi request reprint Characterization of genotypic determinants in HR-1 and HR-2 gp41 domains in individuals with persistent HIV viraemia under T-20
    Anne Genevieve Marcelin
    Pitie Salpetriere Hospital, Paris, France
    AIDS 18:1340-2. 2004
    ..Our results suggest that only HR-1 sequencing is necessary to characterize resistance to T-20, and that HR-2 domain sequencing is probably not required...
  41. ncbi request reprint Parallel decline of CD8+/CD38++ T cells and viraemia in response to quadruple highly active antiretroviral therapy in primary HIV infection
    Richard Tilling
    Department of Immunology and Molecular Pathology, Royal Free and University College Medical School, Royal Free Campus, London NW3 2QG, UK
    AIDS 16:589-96. 2002
    ..To monitor changes in the numbers of CD8 lymphocytes expressing the activated CD38++ phenotype in peripheral blood samples from patients with primary HIV infection (PHI) treated with highly active antiretroviral therapy (HAART)...
  42. pmc Monitoring of cytomegalovirus infection in solid-organ transplant recipients by an ultrasensitive plasma PCR assay
    Karine Hadaya
    Division of Infectious Diseases, University Hospitals of Geneva, 1211 Geneva 14, Switzerland
    J Clin Microbiol 41:3757-64. 2003
    ..This test could improve the monitoring of CMV infection or reactivation in renal transplant recipients...
  43. ncbi request reprint A controlled trial of granulocyte macrophage-colony stimulating factor during interruption of HAART
    Catherine Fagard
    Divisions of Infectious Diseases, University Hospital, Geneva, Geneva, Switzerland
    AIDS 17:1487-92. 2003
    ..To explore the effect of granulocyte macrophage colony stimulating factor (GM-CSF) on viral load and CD4 cell count during interruption of highly active antiretroviral therapy (HAART)...
  44. ncbi request reprint Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts
    Bastien Mangeat
    Department of Genetics and Microbiology, University of Geneva, 1211 Geneva 4, Switzerland
    Nature 424:99-103. 2003
    ..We also find that APOBEC3G can act on a broad range of retroviruses in addition to HIV, suggesting that hypermutation by editing is a general innate defence mechanism against this important group of pathogens...
  45. ncbi request reprint A prospective trial of structured treatment interruptions in human immunodeficiency virus infection
    Catherine Fagard
    Division of Infectious Diseases, Geneva Unmiversity Hospital, 1211 Geneva 14, Switzerland
    Arch Intern Med 163:1220-6. 2003
    ..Many patients who started HAART earlier in their disease course than is currently recommended would like to discontinue, but it is unknown whether it is safe to do so...
  46. ncbi request reprint Residual HIV-specific CD4 and CD8 T cell frequencies after prolonged antiretroviral therapy reflect pretreatment plasma virus load
    Annette Oxenius
    Nuffield Department of Medicine, John Radcliffe Hospital and Peter Medawar Building for Pathogen Research, Oxford, UK
    AIDS 16:2317-22. 2002
    ..This most likely reflects the complex interactions between the virus and these immune effector cells in the absence of treatment...
  47. pmc Improved monitoring of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation by an ultrasensitive plasma DNA PCR assay
    Laurent Kaiser
    Division of Infectious Diseases Division of Hematology Division of Oncology, University Hospital of Geneva, Geneva, Switzerland
    J Clin Microbiol 40:4251-5. 2002
    ..01). This assay improved the monitoring of CMV infection or reactivation in hematopoietic allogeneic stem cell recipients...
  48. pmc Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection
    Annette Oxenius
    Nuffield Department of Medicine, John Radcliffe Hospital and Peter Medawar Building for Pathogen Research, Oxford OX1 3SY, UK
    Proc Natl Acad Sci U S A 99:13747-52. 2002
    ....
  49. ncbi request reprint Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy
    Gilbert Greub
    University Hospital, Lausanne, Switzerland
    AIDS 16:1967-9. 2002
  50. ncbi request reprint A patient with HIV-1 superinfection
    Stephanie Jost
    Division of Infectious Diseases, University of Geneva, Geneva
    N Engl J Med 347:731-6. 2002
  51. ncbi request reprint Analysis of HIV-1- and CMV-specific memory CD4 T-cell responses during primary and chronic infection
    Alexandre Harari
    Laboratory of AIDS Immunopathogenesis, Division of Immunology and Allergy, Department of Medicine, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Switzerland
    Blood 100:1381-7. 2002
    ..These results advance the characterization of antiviral memory CD4 T-cell response and the delineation of the potential mechanisms that likely prevent the generation of a robust CD4 T-cell immune response during primary infection...
  52. ncbi request reprint Low levels of perforin expression in CD8+ T lymphocyte granules in lymphoid tissue during acute human immunodeficiency virus type 1 infection
    Jan Andersson
    Department of Medicine, Center for Infectious Medicine, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden
    J Infect Dis 185:1355-8. 2002
    ..This suggests that mechanisms inhibiting CTL-mediated cytotoxicity are operative in lymphoid tissue early in the course of HIV infection...
  53. ncbi request reprint A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection
    Milos Opravil
    Division of Infectious Diseases, University Hospital, CH 8091 Zurich, Switzerland
    J Infect Dis 185:1251-60. 2002
    ....
  54. ncbi request reprint CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study
    Gilbert R Kaufmann
    Basel Center for HIV Research, Division of Infectious Diseases, University Hospital, Basel, Switzerland
    Arch Intern Med 163:2187-95. 2003
    ..Highly active antiretroviral therapy (HAART) for human immunodeficiency virus (HIV)-1 infection allows recovery of CD4 T lymphocytes. Few studies have explored the long-term T-lymphocyte responses to HAART...
  55. ncbi request reprint Drug resistance mutations during structured treatment interruptions
    Sabine Yerly
    Laboratory of Virology, Geneva University Hospital, Switzerland
    Antivir Ther 8:411-5. 2003
    ..Their HAART was interrupted for 2 weeks and restarted for 8 weeks. After four of these cycles, treatment was definitively interrupted at week 40...
  56. ncbi request reprint Proviral HIV-DNA predicts viral rebound and viral setpoint after structured treatment interruptions
    Sabine Yerly
    AIDS 18:1951-3. 2004
    ....
  57. ncbi request reprint Infrequent transmission of HIV-1 drug-resistant variants
    Sabine Yerly
    Laboratory of Virology and AIDS Center, Geneva University Hospital, Geneva, Switzerland
    Antivir Ther 9:375-84. 2004
    ..These data suggest that drug-resistant variants and in particular multidrug-resistant variants have a substantially reduced transmission capacity...
  58. ncbi request reprint Cytomegalovirus quantification in plasma by an automated real-time PCR assay
    Sabine Yerly
    Laboratory of Virology, University of Geneva Hospitals, 24 Rue Micheli du Crest, 1211 Geneva 14, Switzerland
    J Clin Virol 38:298-303. 2007
    ..Sensitive quantitation of cytomegalovirus (CMV) DNA in blood is helpful for the diagnosis of CMV infection or reactivation and the monitoring of transplanted patients...
  59. ncbi request reprint HIV-1 co/super-infection in intravenous drug users
    Sabine Yerly
    AIDS 18:1413-21. 2004
    ..The frequency of HIV-1 co/super-infection is unknown despite their implications for public health and vaccine development. This issue was addressed during an epidemic of both CRF11 and B subtype among intravenous drug users (IVDUs)...
  60. ncbi request reprint Drug resistance mutations: yes but where?
    Luc Perrin
    AIDS 18:1201-2. 2004
  61. ncbi request reprint Prevalence of human T-cell leukemia virus types I and II in Switzerland
    Jürg Böni
    Swiss National Center for Retroviruses, University of Zurich, Zurich, Switzerland
    J Med Virol 72:328-37. 2004
    ..The finding of low HTLV-I/II prevalence among Swiss blood donors and containment of HTLV-I/II infection within known risk-groups does not support initiation of HTLV-I/II screening for Swiss blood, tissue, and organ donations...
  62. ncbi request reprint Long-term virological response to multiple sequential regimens of highly active antiretroviral therapy for HIV infection
    Gilbert R Kaufmann
    Division of Infectious Diseases, University Hospital, Basel, Switzerland
    Antivir Ther 9:263-74. 2004
    ..Information about the virological response to sequential highly active antiretroviral therapy (HAART) for HIV infection is limited. The virological response to four consecutive therapies was evaluated in the Swiss HIV Cohort...
  63. ncbi request reprint Brief report: incubation and duration of specific symptoms at acute retroviral syndrome as independent predictors of progression to AIDS
    Philippe Vanhems
    Laboratory of Epidemiology and Public Health, INSERM U271, Universite Claude Bernard, Edouard Herriot Hospital, 8 avenue Rockefeller, 69373 Lyon Cedex 08, France
    J Acquir Immune Defic Syndr 32:542-4. 2003
    ..1-8.1, P < 0.03 to P < 0.001). Pathogenetic mechanisms involved in the incubation of ARS features may be associated with progression to AIDS...
  64. ncbi request reprint Accumulation of DC-SIGN+CD40+ dendritic cells with reduced CD80 and CD86 expression in lymphoid tissue during acute HIV-1 infection
    Karin Lore
    Division of Clinical Virology, Department of Microbiology, Pathology and Immunology, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden
    AIDS 16:683-92. 2002
    ..Dendritic cells (DC) are target cells for HIV-1 and play a key role in antigen presentation and activation of T cells...
  65. ncbi request reprint HIV-1 and HCV infections among antibody-negative blood donors
    Josip Begovac
    N Engl J Med 351:2232-5; author reply 2232-5. 2004
  66. pmc Quantifiable cytotoxic T lymphocyte responses and HLA-related risk of progression to AIDS
    Almut Scherer
    Zoology Department, Oxford University, South Parks Road, Oxford OX1 3PS, United Kingdom
    Proc Natl Acad Sci U S A 101:12266-70. 2004
    ..These data provide an immunological mechanism to explain HLA-related risk of progression to AIDS and emphasize the central role of viral evolution in the pathogenesis of HIV...
  67. ncbi request reprint The density of coreceptors at the surface of CD4+ T cells contributes to the extent of human immunodeficiency virus type 1 viral replication-mediated T cell death
    Jean Daniel Lelievre
    INSERM U421, Faculte de Medecine Henri Mondor, Creteil, France
    AIDS Res Hum Retroviruses 20:1230-43. 2004
    ..Our data indicate that the density of chemokine receptors expressed on CD4(+) T cells may be a critical parameters for the cytopathic effect of HIV strains and may have major impact on CD4 T cell depletion during HAART...
  68. ncbi request reprint The incubation period of acute retroviral syndrome as a multistep process: a parametric survival analysis
    Philippe Vanhems
    Laboratory of Epidemiology and Public Health, INSERM U271, Universite Claude Bernard, and Epidemiology Unit, Edouard Herriot Hospital, Lyon, France
    J Acquir Immune Defic Syndr 37:1529-33. 2004
    ....
  69. ncbi request reprint Parallel and overlapping HIV and bloodborne hepatitis epidemics in Africa
    David Gisselquist
    Hershey, Pennsylvania 17033, USA
    Int J STD AIDS 15:145-52. 2004
    ..Across these cohorts, there is a trend for HCV prevalence to increase with HIV, though much of the variance is unexplained. For 25 cohorts with sufficient data, the median relative risk for HCV infection for persons with HIV is 1.52...
  70. pmc Amplicon sequencing and improved detection of human rhinovirus in respiratory samples
    Christelle Deffernez
    Central Laboratory of Virology, Division of Infectious Diseases, Department of Internal Medicine, University Hospitals of Geneva, 24 Rue Micheli du Crest, CH 1211 Geneva 14, Switzerland
    J Clin Microbiol 42:3212-8. 2004
    ..By sequencing the 5' noncoding regions of rhinoviruses recovered from clinical specimens, we designed probes that could specifically detect rhinovirus...
  71. ncbi request reprint Clinical features of acute retroviral syndrome differ by route of infection but not by gender and age
    Philippe Vanhems
    Laboratoire d épidémiologie et de santé publique, and INSERM Unit 271, Faculte de Medecine, Universite Claude Bernard, et Hôpital Edouard Herriot, Lyon, France
    J Acquir Immune Defic Syndr 31:318-21. 2002
    ..52%, p=.01). Genital ulcerations were present only in cases of sexual exposure to HIV. Injecting drug users had or reported symptoms associated with the ARS less frequently than persons acquiring HIV via sexual transmission...
  72. ncbi request reprint Lower respiratory viral illnesses: improved diagnosis by molecular methods and clinical impact
    Jorge Garbino
    Department of Medicine, Division of Infectious Diseases, Central Laboratory of Virology, University Hospitals of Geneva, 24 Rue Micheli du Crest, 1211 Geneva 14, Switzerland
    Am J Respir Crit Care Med 170:1197-203. 2004
    ..These viruses were associated with high morbidity, particularly in lung transplant recipients...